This system delivers CRISPR/Cas9 directly to tumor cells to knock down indoleamine 2,3-dioxygenase-1 (IDO1), a key immunosuppressive mediator often upregulated in aggressive cancers like triple-negative breast cancer. This evidence concerns the gene IDO1 and triple-negative breast carcinoma.